NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

CarcinomaSquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaProstate CancerSmall-cell Lung CancerNon-small Cell Lung CancerCervical CancerOther Solid Tumors

Interventions

DRUG

XNW5004

XNW5004 an EZH2 inhibitor, BID, administered in continuous

DRUG

KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection

KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Trial Locations (1)

528404

RECRUITING

Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou